Sign in
4

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0000950170-23-073837

Chief Commercial Officer acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Olinger Margaret Chief Commercial Officer 2023-12-27 Option exercise +25,000 $0.37 $9,250 276,108 D
Derivatives
Olinger Margaret Chief Commercial Officer 2023-12-27 Option exercise · Stock Option (Right to Buy) −25,000 44,577 D
Loading xslF345X05/ownership.xml…